1909 related articles for article (PubMed ID: 24820015)
1. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
2. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
[TBL] [Abstract][Full Text] [Related]
4. Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.
Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Boulanghien J; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Perret-Liaudet A; Touchon J; Lehmann S
J Alzheimers Dis; 2011; 26(3):553-63. PubMed ID: 21709372
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.
Alcolea D; Vilaplana E; Pegueroles J; Montal V; Sánchez-Juan P; González-Suárez A; Pozueta A; Rodríguez-Rodríguez E; Bartrés-Faz D; Vidal-Piñeiro D; González-Ortiz S; Medrano S; Carmona-Iragui M; Sánchez-Saudinós M; Sala I; Anton-Aguirre S; Sampedro F; Morenas-Rodríguez E; Clarimón J; Blesa R; Lleó A; Fortea J
Neurobiol Aging; 2015 Jun; 36(6):2018-23. PubMed ID: 25865441
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
7. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
9. Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.
Alexopoulos P; Guo LH; Tsolakidou A; Kratzer M; Grimmer T; Westerteicher C; Jiang M; Bujo H; Diehl-Schmid J; Kurz A; Perneczky R
J Alzheimers Dis; 2012; 28(3):543-52. PubMed ID: 22045485
[TBL] [Abstract][Full Text] [Related]
10. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
[TBL] [Abstract][Full Text] [Related]
16. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
18. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.
Baldacci F; Toschi N; Lista S; Zetterberg H; Blennow K; Kilimann I; Teipel S; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Bonuccelli U; Hampel H
Alzheimers Dement; 2017 Sep; 13(9):993-1003. PubMed ID: 28263742
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
[TBL] [Abstract][Full Text] [Related]
20. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
